Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Study:

A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

Rationale:

n/a

Purpose:

This study is looking at whether Metformin, an agent that is commonly used to treat diabetes, can decrease or affect the ability of breast cancer cells to grow and whether Metformin will work with other therapies to keep cancer from recurring. Health Canada has not approved the sale or use of Metformin to treat breast cancer, although they have approved its use in this clinical trial. Although Metformin is approved by the FDA for the treatment of diabetes, its use in breast cancer is considered investigational.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Breast Cancer Drug: metformin hydrochloride
Other: placebo
Phase 3

Verified by NCIC Clinical Trials Group June, 2013

Sponsored by: NCIC Clinical Trials Group
Information provided by: NCIC Clinical Trials Group
ClinicalTrials.gov identifier: NCT01101438

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Pamela J. Goodwin, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site